Noe PCI her og der 
Posted by Carrie Lamoureux on July 27, 2019 at 11:12 pm
Analysts expect Moderna, Inc. (NASDAQ:MRNA) to report $-0.41 EPS on August, 8.After having $-0.40 EPS previously, Moderna, Inc.’s analysts see 2.50 % EPS growth. The stock increased 4.52% or $0.61 during the last trading session, reaching $14.12. About 669,060 shares traded. Moderna, Inc. (NASDAQ:MRNA) has 0.00% since July 28, 2018 and is . It has underperformed by 4.43% the S&P500.
Marina Biotech, Inc., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company has market cap of $4.65 billion. The firm has three clinical development programs, such as IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication of familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. It currently has negative earnings. The Company’s preclinical pipeline includes oligotherapeutics for the treatment of bladder cancer, inflammatory bowel, and duchenne muscular dystrophy diseases.
More notable recent Moderna, Inc. (NASDAQ:MRNA) news were published by: Globenewswire.com which released: “PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company – GlobeNewswire” on July 22, 2019, also [Nasdaq.com]***(https://www.nasdaq.com/article/mrna-crosses-above-average-analyst-target-cm1125718) with their article: “MRNA Crosses Above Average Analyst Target – Nasdaq” published on April 08, 2019, Fool.com published: “Is Moderna a Buy? – Motley Fool” on February 14, 2019. More interesting news about Moderna, Inc. (NASDAQ:MRNA) were released by: Nasdaq.comand their article: “Here’s Why Moderna Lost 29.6% in June – Nasdaq” published on July 09, 2019 as well as Seekingalpha.com‘s news article titled: “Eloxx Pharmaceuticals: Buy, Sell Or Hold? – Seeking Alpha” with publication date: July 10, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
